RxDoctor Payments Data

Elizabeth Fanning

Family · Superior, CONPI 1699328120

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 50 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$598
  • Novo Nordisk$195
  • Insulet Corporation$84
  • Dexcom, Inc.$68
  • Neurocrine Biosciences, Inc.$61
  • Aimmune Therapeutics, Inc.$41
  • plus $343 from 16 others

What the payments were for

  • Travel & lodging$45232%
  • Food & beverage$93968%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,391 in reported general payments places this provider in the 80th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$20,039
Medicare patients
129
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$22,212
XareltoRivaroxaban11$8,080
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,000
Albuterol Sulfate HfaAlbuterol Sulfate32$751
Rosuvastatin Calcium50$743
Levothyroxine Sodium74$668
Omeprazole48$564
Gabapentin28$554
Lisinopril68$537
ValacyclovirValacyclovir Hcl16$492
Losartan Potassium46$490
Duloxetine Hcl17$488
Atorvastatin Calcium57$483
Metoprolol Succinate40$457
Tramadol Hcl19$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$195$22,21217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,182 family providers in Colorado.

Other family in Superior

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →